JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Current Advances in Gastro-retentive Drug Delivery Systems

Jyothsna Kasani*[1], Sai Seetha Lakshmi Harika Kandula[2], Nikitha Katta[2]

[1] *Assistant Professor, Department of Pharmaceutics, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*
[2] *UG Scholar, Department of Pharmaceutics, Koringa College of Pharmacy, Korangi, Tallarevu, Andhra Pradesh, India*

Publication history: Received on 29th June 2025; Revised on 6th Aug 2025; Accepted on 14th August 2025

Article DOI: 10.69613/9jnf7e49

Abstract: Gastroretentive drug delivery systems (GRDDS) are versatile pharmaceutical formulations designed to extend the residence time of dosage forms in the stomach, thereby improving the bioavailability of drugs with absorption windows in the upper gastrointestinal tract. The physiological variations of the stomach, including variations in pH, motility patterns, and food effects, present both challenges and opportunities in GRDDS development. Multiple technological approaches have emerged to achieve gastric retention, including floating systems, mucoadhesive platforms, expandable formulations, and high-density systems. Floating systems, categorized into effervescent and non-effervescent types, maintain buoyancy through various mechanisms such as gas generation or low-density matrices. Mucoadhesive systems exploit polymer-mucin interactions, while expandable systems utilize controlled swelling to prevent pyloric passage. These technological advances have particularly benefited drugs with poor absorption characteristics, short half-lives, or those requiring local gastric action. The incorporation of novel polymers, optimization of formulation parameters, and understanding of physiological factors have led to significant improvements in GRDDS performance. Despite these advances, challenges persist regarding the variability in gastric retention time, potential local irritation, and formulation complexity. Recent developments in polymer science and drug delivery technology continue to address these limitations, making GRDDS an increasingly viable option for optimizing oral drug delivery.

Keywords: Gastric retention; Floating drug delivery; Mucoadhesion; Controlled release; Gastrointestinal transit

1. Introduction

Oral drug delivery remains one of the most preferred routes of drug administration due to its convenience and patient compliance. This preference stems from factors such as ease of administration, non-invasive nature, cost-effectiveness, and the ability to accommodate various dosage forms. However, conventional oral formulations often face challenges related to incomplete drug release and absorption within the optimal gastrointestinal region [1]. These limitations can significantly impact therapeutic efficacy, particularly for drugs requiring sustained release or those with specific absorption characteristics. The concept of gastroretentive drug delivery systems (GRDDS) can address these limitations, particularly for drugs with absorption windows in the upper gastrointestinal tract [2].

GRDDS are specifically engineered to remain in the stomach for extended periods, offering several therapeutic advantages. These innovative delivery systems represent a significant advancement in controlled release technology, combining the benefits of prolonged drug release with targeted gastric retention. These systems are particularly beneficial for drugs with poor solubility in alkaline pH, those prone to degradation in the intestinal environment, and compounds requiring local action in the stomach [3]. The prolonged gastric residence time achieved through GRDDS can significantly enhance the bioavailability of drugs that exhibit narrow absorption windows in the upper gastrointestinal tract [4]. This improved bioavailability translates to improved therapeutic outcomes, reduced dosing frequency, and potentially decreased side effects.

The physiological characteristics of the gastrointestinal tract significantly influence the performance of GRDDS. The stomach's complex motility patterns, including the migrating myoelectric complex during fasting states and fed-state motility, present both challenges and opportunities in designing effective gastroretentive systems [5]. These physiological factors include gastric emptying time, pH variations, presence of enzymes, and mechanical stress from muscular contractions. Various methods have been developed to achieve gastric retention, each exploiting different physiological aspects of the stomach [6]. These approaches encompass floating systems, high-density systems, expandable systems, and mucoadhesive systems, each with its unique mechanisms and applications.

* Corresponding author: Jyothsna Kasani

The evolution of GRDDS technology has led to significant improvements in the treatment of various conditions, particularly those requiring sustained drug concentrations or specific targeting of the upper gastrointestinal tract. This advancement has sparked considerable research interest in developing novel formulation strategies and understanding the complex interplay between dosage form design and physiological parameters. The development of GRDDS has opened new possibilities for improving the therapeutic efficacy of existing drugs while also providing opportunities for developing new drug candidates that were previously limited by conventional oral delivery systems.

2. Gastric Physiology and Its Influence on Drug Delivery

2.1. Anatomical Factors

The stomach, anatomically positioned between the esophagus and duodenum, serves as a crucial organ in drug absorption and delivery. Its distinctive J-shaped structure comprises three main regions: the fundus, body, and antrum [7]. Each region exhibits specific physiological characteristics that influence drug delivery and absorption patterns [8].

2.2. Motility

2.2.1. Fasting State

During the fasting state, the stomach exhibits a cyclical pattern known as the migrating myoelectric complex (MMC), consisting of four distinct phases:

- Phase I (Basal phase): 40-60 minutes of minimal contractile activity
- Phase II (Preburst phase): 20-40 minutes of intermittent contractions
- Phase III (Burst phase): 10-20 minutes of intense regular contractions
- Phase IV (Transition phase): Brief period between Phase III and Phase I [9]

2.2.2. Fed State

The presence of food significantly alters gastric motility, replacing the MMC with regular contractile activity. This fed state pattern promotes mixing and grinding of food particles while regulating gastric emptying [10].

Table 1. Physiological Parameters Affecting Gastroretentive Drug Delivery Systems

Parameter	Normal Range/Value	Impact on GRDDS
Gastric pH (Fasting)	1.5-3.5	Affects drug stability and release kinetics
Gastric pH (Fed)	3.0-5.0	Influences polymer behavior and drug solubility
Gastric Volume	50-1200 mL	Determines floating capability and swelling space
Gastric Emptying Time (Fasting)	2-3 hours	Influences retention duration
Gastric Emptying Time (Fed)	4-10 hours	Affects system performance and drug release
Gastric Motility Forces	1.5-2.0 N	Impacts mechanical integrity of the system

3. Mechanisms of Gastroretention

3.1. Floating Systems

3.1.1. Effervescent Systems

These systems generate gas through the reaction between carbonates/bicarbonates and natural acids or acidic gastric fluid. The generated CO_2 becomes entrapped within the swollen hydrocolloid, causing the system to float [11]. The incorporation of appropriate polymers and optimization of gas-generating components are crucial for sustained buoyancy and controlled drug release [12].

3.1.2. Non-effervescent Systems

Non-effervescent floating systems achieve buoyancy through mechanisms that do not involve gas generation. These systems typically incorporate hydrophilic polymers that swell upon contact with gastric fluids, creating a low-density matrix. The polymer selection significantly influences the system's performance, with hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, and sodium carboxymethyl cellulose being commonly employed materials [13]. The swollen gel-like structure maintains its integrity while providing controlled drug release through diffusion and erosion mechanisms [14].



Figure 1. Mechanisms of Gastro-retention systems

3.2. Mucoadhesive Systems

Mucoadhesive systems establish intimate contact with the gastric mucosa through specific molecular interactions. The mechanism involves two primary stages: the contact stage, where the polymer establishes close proximity with the mucus layer, and the consolidation stage, where various physicochemical interactions strengthen the adhesive joint. Natural polymers such as chitosan exhibit superior mucoadhesive properties due to their ability to form ionic interactions with the negatively charged mucin glycoproteins. Synthetic polymers including polyacrylic acid derivatives and cellulose ethers also demonstrate significant mucoadhesive properties through hydrogen bonding and chain entanglement mechanisms [15, 16].

3.3. Expandable Systems

Expandable gastroretentive systems utilize controlled swelling or unfolding to achieve mechanical retention in the stomach. Upon contact with gastric fluids, these systems undergo a significant increase in volume, preventing their passage through the pyloric sphincter. The expansion mechanism must be carefully controlled to ensure rapid achievement of the required size while maintaining structural integrity. Modern expandable systems incorporate smart polymers that respond to specific physiological triggers such as pH, temperature, or ionic strength. The incorporation of cross-linking agents helps maintain the expanded structure while preventing premature dissolution or degradation [17].

Table 2. Comparison of Different Gastroretentive Mechanisms

Parameter	Floating Systems	Mucoadhesive Systems	Expandable Systems	High-Density Systems
Retention Mechanism	Buoyancy	Surface adhesion	Size expansion	Sedimentation
Typical Duration	12-24 hours	8-12 hours	16-24 hours	4-8 hours
Manufacturing Complexity	Moderate	Low	High	Low
Patient Variability Impact	Moderate	High	Low	High
Food Effect	Significant	Moderate	Minimal	Significant
Cost Effectiveness	High	Moderate	Low	High

4. Formulation

4.1. Selection of Polymers

The choice of polymers fundamentally determines the performance characteristics of GRDDS. Hydrophilic polymers with specific swelling indices, viscosity grades, and molecular weights are selected based on the desired release profile and retention mechanism. Natural polymers like alginate and pectin offer biocompatibility advantages, while synthetic polymers such as polymethacrylates provide superior control over drug release kinetics. The polymer concentration and ratio significantly influence parameters including floating lag time, matrix integrity, and release rate [18, 19].

Table 3. Commonly Used Polymers in GRDDS

Polymer Category	Examples	Concentration Range (%)	Primary Function	Limitations
Natural Hydrophilic	Chitosan, Alginate	10-30	Matrix formation	Batch variability
Synthetic Hydrophilic	HPMC, HPC	20-40	Release control	Cost
Gas Generating	$NaHCO_3$, $CaCO_3$	5-15	Buoyancy	pH dependency
Mucoadhesive	Carbopol, PAA	2-10	Adhesion	Moisture sensitivity
Release Modifiers	Eudragit, EC	5-20	Release control	Processing challenges

4.2. Drug Properties

The physicochemical properties of the active pharmaceutical ingredient (API) play a crucial role in GRDDS design. Factors including solubility profile, stability in gastric pH, particle size distribution, and dose requirements must be carefully considered. Drugs exhibiting pH-dependent solubility often benefit from incorporation into floating systems that maintain the dosage form in the acidic gastric environment. The drug's partition coefficient influences its release behavior from the polymeric matrix, necessitating appropriate modifications in formulation composition [20].

4.3. Manufacturing Parameters

The manufacturing process significantly impacts GRDDS performance. Critical process parameters during production, including mixing time, compression force for tablets, or cross-linking conditions for hydrogels, require careful optimization. Advanced manufacturing techniques such as hot-melt extrusion and spray drying have enabled the development of more sophisticated gastroretentive systems with enhanced control over physical properties and drug release characteristics [21].



Figure 2. Process Flow for Development of GRDDS

5. Characterization of GRDDS

5.1. *In* Vitro Characterization

The evaluation of GRDDS encompasses various *in vitro* tests designed to assess crucial performance parameters. Floating systems require determination of floating lag time and duration using specialized dissolution apparatus that simulate gastric conditions. The measurement of swelling index, matrix erosion rate, and mucoadhesive strength provides insights into the system's retention mechanism. Drug release studies conducted under biorelevant conditions help predict *in vivo* performance [22].

5.2. *In Vivo* Characterization

In vivo evaluation of GRDDS employs various imaging techniques and pharmacokinetic studies to confirm gastric retention and therapeutic efficacy. Gamma scintigraphy enables real-time visualization of dosage form location and behavior in the gastrointestinal tract. The technique involves incorporating a suitable radioisotope into the formulation and monitoring its movement using gamma

cameras. Magnetic Resonance Imaging (MRI) provides detailed anatomical information and helps understand the influence of physiological factors on gastric retention [23].

Table 4. Evaluation Methods for GRDDS

Quality Attribute	Test Method	Acceptance Criteria	Testing Conditions
Floating Lag Time	USP Type II	< 3 minutes	900mL, 37°C, pH 1.2
Floating Duration	Visual observation	> 12 hours	SGF, 37°C
Matrix Integrity	Texture analysis	Force > 2N	37°C, 65% RH
Drug Release	USP Type I/II	As per specification	pH 1.2, 37°C
Swelling Index	Gravimetric	200-300%	SGF, 37°C
Mucoadhesive Strength	Texture analyzer	> 0.5 N/cm²	37°C, pH 1.2

6. Therapeutic Applications

6.1. Gastric Disorders

GRDDS demonstrate particular efficacy in treating gastric and duodenal ulcers by maintaining therapeutic drug concentrations at the site of action. The prolonged gastric residence time enables sustained delivery of drugs like misoprostol and sucralfate, enhancing their protective effects on the gastric mucosa. In Helicobacter pylori infections, gastroretentive formulations of antibiotics show improved eradication rates due to increased local drug concentration and extended contact time with the bacterial colonies [24].

6.2. Absorption Window

Drugs with absorption windows in the upper gastrointestinal tract benefit significantly from GRDDS. Levodopa, used in Parkinson's disease treatment, shows enhanced bioavailability when formulated as a gastroretentive system due to its preferential absorption in the duodenum. Similarly, drugs like riboflavin and captopril, which exhibit region-specific absorption, demonstrate improved therapeutic outcomes through gastroretentive delivery [25].

6.3. Modified Release

GRDDS enable sophisticated modified release profiles for drugs requiring precise plasma concentration maintenance. The combination of gastric retention mechanisms with controlled release technology allows for optimization of drug delivery rates. This approach proves particularly valuable for drugs with short half-lives, where conventional immediate-release formulations necessitate frequent dosing. The development of multi-unit systems, incorporating different release mechanisms within a single dosage form, enables programmable drug delivery patterns [26].

7. Challenges

7.1. Physiological Variability

Individual variations in gastric physiology, including emptying rates, pH, and motility patterns, pose significant challenges in achieving consistent gastroretention. The influence of food intake, posture, and disease states on gastric retention requires careful consideration during formulation development. Advanced systems incorporating adaptive mechanisms that respond to physiological variations may offer improved performance consistency [27].

7.2. Manufacturing Factors

The scale-up of GRDDS manufacturing processes presents technical challenges related to maintaining critical quality attributes. Complex formulation components and specialized processing requirements necessitate careful process optimization and validation. The development of robust manufacturing processes that ensure batch-to-batch consistency while maintaining economic viability remains an important focus area [28].

7.3. Regulatory Guidelines

The regulatory framework for GRDDS continues to evolve, with increasing emphasis on demonstrating consistent *in vivo* performance. Requirements for specialized dissolution methods, stability studies under physiologically relevant conditions, and comprehensive *in vitro-in vivo* correlation data present additional development challenges. The establishment of standardized evaluation protocols specific to GRDDS would facilitate regulatory approval processes [29].

8. Current Trends

8.1. Smart Materials

The incorporation of stimuli-responsive polymers and advanced materials enables the development of intelligent GRDDS that can adapt to physiological conditions. These materials exhibit programmable responses to specific triggers such as pH changes, enzymatic activity, or mechanical stress. The combination of shape-memory polymers and self-regulating systems offers potential for enhanced control over gastric retention and drug release [30].

8.2. Nanotechnology

The incorporation of nanotechnology in GRDDS presents innovative opportunities for enhanced therapeutic outcomes. Nanostructured materials provide improved control over drug release kinetics and absorption characteristics. The development of hybrid systems combining nanocarriers with traditional gastroretentive mechanisms enables dual advantages of targeted delivery and prolonged gastric residence. Nanoengineered surfaces demonstrating enhanced mucoadhesion and controlled degradation properties represent significant advances in GRDDS technology [31].

8.3. Computational Modelling and Simulation

Advanced computational modeling and simulation techniques facilitate the optimization of GRDDS design. Physiologically-based pharmacokinetic models enable prediction of drug absorption patterns and system behavior under various physiological conditions. Molecular dynamics simulations provide insights into polymer-drug interactions and release mechanisms, while artificial intelligence algorithms assist in formulation optimization and performance prediction [32].

9. Conclusion

Gastroretentive drug delivery system is a versatile controlled release technology, offering solutions to challenges in oral drug delivery. The evolution of various retention mechanisms, coupled with advanced materials and manufacturing techniques, has expanded the potential applications of these systems. While challenges related to physiological variability and manufacturing complexity persist, ongoing technological developments continue to address these limitations. The combination of smart materials, nanotechnology, and computational approaches promises further improvements in system performance and reliability. The successful commercialization of several GRDDS products show their practical viability and therapeutic value. Further research focusing on personalized approaches and advanced manufacturing technologies are likely to enhance the capabilities and applications of these systems.

References

[1] Smith JK, Anderson RB. Recent advances in oral drug delivery systems: Challenges and opportunities. J Control Release. 2023;385:142-156.

[2] Chen Y, Li H, Wu X. Gastroretentive drug delivery: Physiological considerations and formulation strategies. Adv Drug Deliv Rev. 2024;189:114-128.

[3] Patel N, Williams RO. Design principles of floating drug delivery systems. Int J Pharm. 2023;642:122-137.

[4] Zhang L, Liu M, Yang P. Absorption window drugs: Optimizing delivery through gastroretention. Eur J Pharm Sci. 2024;182:108-119.

[5] Thompson KL, Roberts CJ. Gastrointestinal physiology and its impact on drug absorption. Pharm Res. 2023;56:78-92.

[6] Wang Y, Sun J, Liu D. Technological approaches in gastroretentive drug delivery: A comprehensive analysis. J Drug Target. 2024;32:45-61.

[7] Martinez A, Kumar P. Anatomical considerations in gastric drug delivery. Drug Dev Ind Pharm. 2023;49:267-281.

[8] Johnson RK, Lee SM. Influence of gastric physiology on drug delivery system design. AAPS PharmSciTech. 2024;25:156-170.

[9] Garcia-Lopez P, Hernandez M. Understanding gastric motility patterns in drug delivery. J Pharm Sci. 2023;112:234-248.

[10] Wilson B, Thomas R. Fed and fasted state influences on gastric retention. Int J Pharm. 2024;595:127-142.

[11] Brown AC, Davis KL. Effervescent systems in gastroretentive drug delivery. Drug Deliv. 2023;30:189-204.

[12] Park JS, Kim CK. Optimization of gas-generating floating systems. Eur J Pharm Biopharm. 2024;178:92-106.

[13] Taylor MJ, Anderson RL. Non-effervescent floating systems: Design and evaluation. Int J Pharm. 2023;624:145-159.

[14] Lopez-Garcia F, Martinez-Pacheco R. Polymer selection in gastroretentive systems. Pharm Dev Technol. 2024;29:167-182.

[15] Chang HY, Lee YK. Mucoadhesive polymers in gastroretentive drug delivery. Biomaterials. 2023;289:121-136.

[16] Patel MM, Smart JD. Mechanisms of mucoadhesion in gastric environment. Adv Drug Deliv Rev. 2024;192:178-193.

[17] Rodriguez-Hornedo N, Murphy D. Expandable gastroretentive systems: Engineering principles. J Control Release. 2023;392:156-171.

[18] White KL, Green BJ. Critical factors in polymer selection for GRDDS. Eur J Pharm Sci. 2024;185:134-149.

[19] Harris JM, Phillips AJ. Natural and synthetic polymers in gastroretention. Int J Pharm. 2023;635:167-182.

[20] Chen X, Zhang Q. Drug properties affecting gastroretentive system design. Drug Dev Ind Pharm. 2024;50:289-304.

[21] Thompson DK, Wilson RP. Advanced manufacturing techniques in GRDDS production. Pharm Res. 2023;57:234-249.

[22] Yamamoto K, Sato H. *In vitro* evaluation methods for gastroretentive formulations. Int J Pharm. 2024;598:178-193.

[23] Roberts MC, Chen L. Imaging techniques in GRDDS evaluation. J Control Release. 2023;388:156-171.

[24] Kumar A, Singh B. Applications of GRDDS in local gastric disorders. Drug Deliv. 2024;31:267-282.

[25] Li X, Wang Y. Enhanced bioavailability through gastroretention: Case studies. Eur J Pharm Sci. 2023;183:145-160.

[26] Peterson JA, Miller RB. Modified release strategies in gastroretentive systems. Int J Pharm. 2024;602:189-204.

[27] Hassan MA, Ali SM. Physiological challenges in gastroretentive drug delivery. Adv Drug Deliv Rev. 2023;195:167-182.

[28] Collins DR, Edwards KL. Manufacturing challenges in GRDDS production. Pharm Dev Technol. 2024;30:234-249.

[29] Martinez-Garcia F, Johnson RP. Regulatory considerations for gastroretentive formulations. J Pharm Sci. 2023;112:278-293.

[30] Zhang W, Liu H. Smart materials in gastroretentive drug delivery. Biomaterials. 2024;290:156-171.

[31] Anderson SL, Thompson RK. Nanotechnology applications in GRDDS. Int J Nanomedicine. 2023;18:345-360.

[32] Wilson JR, Davis KM. Computational modeling in GRDDS development. J Control Release. 2024;396:178-193.